DMRA
NASDAQDamora Therapeutics Inc.
Damora Therapeutics Inc. (DMRA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for DMRA, including 1 press release or news item, 1 SEC filing and 1 earnings update. The most recent was published Nov 4, 2026.
DMRA rankings
Financial highlights
Full financials- Net income, TTM
- -$291.68M
- Cash
- $349.66M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks37+50%
2026-05-102026-11-01
Mix2290d
- SEC Filings11(50%)
- Other6(27%)
- Insider3(14%)
- Leadership1(5%)
- Earnings1(5%)
Latest news
25 items- PRDamora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, includingthe U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activityto be presented at the American Society of Hematology (ASH) 2026 Annual Meeting -- -- Strong financial position with $528.5 million in cash, cash equivalents, and marketable securities as ofSeptember 30, 2026, expected to fund operations into 2H 2029 -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with
- SECSEC Form 10-Q filed by Damora Therapeutics Inc.10-Q - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the acceptance of preclinical data highlighting the best-in-class potential of DMR-001 for poster presentation at the 2026 ASH Annual Meeti
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a 10-year term and an exercise pr
- INSIDERDirector, President and CEO Jarrett Jennifer bought $252,875 worth of Ordinary Shares (12,500 units at $20.23), increasing direct ownership by 2% to 512,500 units (SEC Form 4)4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of options to purchase an aggregate of 135,400 Damora ordinary shares with a 10-year term and an exercis
- INSIDERSEC Form 4 filed by Director Cheng Andrew4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cheng Andrew3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SECSEC Form EFFECT filed by Damora Therapeutics Inc.EFFECT - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form POSASR filed by Damora Therapeutics Inc.POSASR - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form S-8 POS filed by Damora Therapeutics Inc.S-8 POS - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECSEC Form POS AM filed by Damora Therapeutics Inc.POS AM - Damora Therapeutics, Inc. (0001800315) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by Damora Therapeutics Inc.8-A12B/A - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights– Initiated the Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin (mutCALR)-driven essential thrombocythemia (ET) and myelofibrosis (MF) – – Presented DMR-001 preclinical data at the European Hematology Association (EHA) 2026 Congress, showcasing best-in-class potential – – Appointed biotech veteran Dr. Andrew Cheng to the Board of Directors – – Strong financial position with $540.5 million in cash and cash equivalents as of June 30, 2026, expected to fund operations into the second half of 2029 – WALTHAM, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefin
- SECSEC Form 10-Q filed by Damora Therapeutics Inc.10-Q - Damora Therapeutics, Inc. (0001800315) (Filer)
- PRDamora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis-- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational mo
- PRDamora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ:DMRA) ("Damora"), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of options to purchase an aggregate of 451,000 Damora ordinary shares with a 10-year term and an exercise pric
- ANALYSTJefferies initiated coverage on Damora Therapeutics with a new price targetJefferies initiated coverage of Damora Therapeutics with a rating of Buy and set a new price target of $50.00
DMRA FAQ
9 questionsWhat is the latest news on DMRA?
In the last 30 days Quantisnow tracked 3 wire items for DMRA: 1 press release or news item, 1 SEC filing and 1 earnings update. The most recent was published on November 4, 2026.Is DMRA profitable?
No. Damora Therapeutics Inc. reported a net loss of $291.68M for the twelve months ended Sep 30, 2026.How much cash and debt does DMRA have?
Damora Therapeutics Inc. reported $349.66M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does DMRA stock trade?
Damora Therapeutics Inc. (DMRA) is listed on NASDAQ.What sector and industry is DMRA in?
Damora Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Damora Therapeutics Inc. go public?
Damora Therapeutics Inc. (DMRA) completed its IPO in 2020.What are analysts saying about DMRA?
Damora Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $50.00 price target on 2026-07-27. Recent price targets range from $35.00 to $50.00.What companies are similar to DMRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare DMRA side-by-side with any of them on Quantisnow.How can I track DMRA on Quantisnow?
Quantisnow aggregates Damora Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DMRA to receive live email and push alerts on every new disclosure.